Skeletal maturity was not accelerated by treatment with recombinant growth hormone ( hGH ) .
BACKGROUND Turner syndrome ( TS ) affects about one in 1500 to 2500 live-born females .
One of the most prevalent and salient features of the syndrome is extremely short stature .
Untreated women are approximately 20 to 21 cm shorter than normal women within their respective population s. Recombinant human growth hormone ( hGH ) has been used to increase growth and final height in girls who have Turner syndrome .
OBJECTIVES To assess the effects of recombinant growth hormone in children and adolescents with TS .
Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: Effect on growth, IGF-I and IGFBP-3 concentrations
Thirty-nine girls with Ullrich-Turner syndrome ( UTS ) ( median age 9.5 years ) were treated with growth hormone ( GH ) with either 12 or 18 IU/m2 per week for 12 months followed by combination therapy with either ox and rolone ( Ox ) ( 0.0625 mg/kg/day po ) or low-dose testosterone ( T ) ( 5 mg i m every 2 weeks ) . Growth velocity improved significantly after 12 IU/m2 per week ( 6.4±1.7 cm/year vs 4.0±1.3 cm/year , x±SD , P<0.001 ) and 18 IU/m2 per week of GH ( 6.5±1.3 cm/year vs 4.5±1.4 cm/year , P<0.001 ) . Ox , but not T was effective in maintaining growth velocity during the 2nd year of therapy ( 6.9±1.3 vs 5.3±1.5 cm/year ) . Basal insulin-like growth factor-I ( IGF-I ) concentrations were in the lower normal range and increased significantly in patients treated with 18 IU/m2 per week ( 357±180 ng/ml vs 160±84 ng/ml ) and 12 IU/m2 per week ( 273±121 ng/ml vs 140±77 ng/ml ) . IGF-I concentrations increased further after addition of Ox ( 533±124 ng/ml , P<0.001 ) or T ( 458±158,P<0.05 ) . IGFBP-3 concentrations were in the upper normal range before therapy and increased only moderately in both GH dosage groups . However , IGF binding protein-3 ( IGFBP-3 ) concentrations were not affected by additional Ox or T treatment . Conclusions 1 . Conventional GH doses are effective in increasing growth velocity in UTS , especially , when combined with Ox . This additive effect is not evident when GH is combined with low dose T. 2 . Changes in growth velocity are accompanied by an increase of the IGF-I/IGFBP-3 ratio . 3 . Ox obviously acts by increasing IGF-I levels independent of the GH status
Skeletal maturity was not accelerated by treatment with recombinant growth hormone ( hGH ) .
BACKGROUND Turner syndrome ( TS ) affects about one in 1500 to 2500 live-born females .
One of the most prevalent and salient features of the syndrome is extremely short stature .
Untreated women are approximately 20 to 21 cm shorter than normal women within their respective population s. Recombinant human growth hormone ( hGH ) has been used to increase growth and final height in girls who have Turner syndrome .
OBJECTIVES To assess the effects of recombinant growth hormone in children and adolescents with TS .